Retatrutide Week by Week: Month 1 to Month 12

Direct answer: The published anchors are week 24 and week 48. In the phase 2 obesity trial the 12mg arm averaged −17.4% and −24.2% at those two visits. No trial has published a week-4 or week-12 body weight for retatrutide, so every figure you see for those weeks — including the ones in the phase table below — is a projection. Running that arm's own published early rate of 0.72% of body weight per week forward gives roughly 3% by week 4 and 8–9% by week 12. Side effects are worst in the opening weeks and around each dose step, and improve substantially after that. Phase 3 pushes the curve further out: TRIUMPH-1 participants on 12mg averaged 28.3% at 80 weeks, so month 12 is not where the line flattens.

Key Takeaways

• Retatrutide works in distinct phases — what you feel at week 2 looks nothing like what you feel at week 24
• Users consistently report side effects hitting hardest in the first weeks and around each dose step, then easing — neither trial published adverse events by week, so that arc is experience rather than data
• The stall-then-drop pattern is a community report, not a trial finding — both trials weighed participants only at fixed visits and published no week-to-week curve
• The top doses did produce the most loss, but the gap is narrower than it looks: at week 48 the phase 2 8mg and 12mg arms were 2.5 percentage points apart (−21.7% vs −24.2%)
• Stalling after weeks of progress usually means it's time to assess calories, not panic
• Dose does matter, and the trials say so: at 80 weeks TRIUMPH-1 read −19.0% at 4mg, −25.9% at 9mg and −28.3% at 12mg. No trial has tested adherence as a variable, so anyone ranking it against dose is guessing
• Trial weight loss is front-loaded: the phase 2 12mg group averaged 0.72% of body weight per week through week 24, then 0.28% per week from week 25 to week 48
• The line did not flatten at 12 months — phase 3 participants kept losing through week 80, and a BMI ≥35 subgroup kept losing through week 104

Every phase of this protocol has a personality. The first month feels like your body is adjusting to something powerful. Months 2–3 feel like momentum you can actually feel. Months 6–12 test whether you're willing to stay patient when the scale gets stubborn. This guide maps it out phase by phase so you know exactly what you're looking at — the good, the frustrating, and the parts most timelines skip.

Why the Retatrutide Timeline Is Different From Other GLP-1s

Before you can understand the week-by-week progression, you need to know why retatrutide behaves differently from semaglutide or tirzepatide. It hits three receptors simultaneously:

• GLP-1 — slows gastric emptying, reduces appetite, drives satiety signaling
• GIP — improves insulin sensitivity, helps partition energy away from fat storage
• Glucagon — in preclinical work in male mice, glucagon receptor activation raised energy expenditure and lowered liver triglycerides. No human energy-expenditure measurement has been published for retatrutide

No published study times each receptor's contribution separately, so the familiar line that GLP-1 acts in hours, GIP over weeks and glucagon over months is not something the literature supports. What is published is the pharmacokinetics: retatrutide's half-life is approximately 6 days, which means blood levels keep accumulating for several weeks after every dose step rather than arriving all at once. That, plus a titration schedule that takes four months to reach the top dose, is why the timeline is longer and more gradual than people expect. For a minority, the loss outpaces what they intended — see losing too much weight on retatrutide.

You're not just suppressing hunger. The glucagon arm is meant to move energy expenditure too — though so far that has been demonstrated in mice, not measured in the human trials. Either way, the process takes time.

Master Retatrutide Timeline Table

How to read that table. Only two cells in the weight column are trial results: −17.4% at week 24 and −21.7% to −24.2% at week 48, both from the phase 2 obesity trial. Everything else is that trial's 12mg arm rate (0.72% of body weight per week through week 24, 0.28% per week after it) carried forward to the end of each phase. It is arithmetic off a group average, not a measurement, and the real early weeks tend to run below it because the dose is still climbing. The dose column is a blend of the two trials as well: phase 2 stepped 2→4→8→12mg and phase 3 stepped 2→4→6→9→12mg, so a 10mg week appears in neither schedule.

Retatrutide Weight Loss Per Week: What the Trials Actually Measured

Almost every "retatrutide weight loss per week" figure circulating online is somebody's forum log. The trials are stricter than that. The phase 2 obesity trial randomised 338 participants and tabulated body weight at exactly two timepoints — week 24 and week 48. The published paper plots a curve between them, but no intermediate value was ever reported as a number, so everything in between, including the phase table above, is interpolation.

Here is the arithmetic with no smoothing applied: take the least-squares mean percent change at each published timepoint and divide by the number of weeks in that stretch.

Two things fall out of that table.

The first half of the year ran about two and a half times faster than the second. At 12mg the average was 0.72% of body weight per week through week 24 and 0.28% per week after it. Trial participants started at a mean of 107.7kg (237 lbs), so those rates work out to roughly 1.7 lbs per week early and 0.7 lbs per week late — an average of 1.2 lbs per week across the full 48 weeks. If your rate halves somewhere in month 6, you are not failing the protocol. You are on the trial curve.

The dose gap opens late. At week 24 the 12mg group was barely ahead of the 8mg group (−17.4% vs −16.6%). By week 48 the gap had widened to 2.5 percentage points (−24.2% vs −21.7%). Chasing the top dose buys you very little in the first six months and most of its advantage in the second.

What That Looks Like in Pounds at Your Starting Weight

Percentages scale across body sizes. Pounds do not. Multiply your own starting weight by the trial percentages:

*The week 80 column comes from the phase 3 TRIUMPH-1 readout, where the average participant started at 112.7kg (248.5 lbs) with a BMI of 40.

These are group averages, and the spread around them is wide. In the phase 2 12mg arm at 48 weeks, 83% of participants lost at least 15% of body weight, 64% lost at least 20%, 48% lost at least 25% and 26% lost at least 30%. Nobody's individual line matches the mean.

If You Are Only a Few Weeks In

No trial published a week-7, week-9 or week-12 body weight for retatrutide, so there is no honest way to quote one. The only defensible math for a short horizon is to apply the early-phase rate to your own weight and label it a projection.

The early weeks sit at the slow end of the range because the dose is still 2–4mg and blood levels have not reached steady state. The 1mg arm — the closest thing the trial has to a low-dose reference — averaged 0.30% per week over its first 24 weeks, and the 4mg arm averaged 0.50%. Applying 0.3–0.6% per week to a 290 lb male still at 2mg gives roughly 6–12 lbs by week 7. That is a projection off trial averages, not a trial result, and it will look nothing like the 20 lb first-month screenshots that circulate on forums.

The Trial Dose Schedule, Week by Week

The phase 3 program used one fixed escalation rule: every participant started at 2mg once weekly and stepped up every four weeks until reaching their assigned target dose. That gives an exact week-to-milligram map, which is the closest thing to an authoritative answer for how much reta you take in any given week.

Three details worth flagging:

• Phase 3 used 9mg, not 8mg. The 8mg step in the phase table above comes from the phase 2 trial. The 10mg step comes from neither trial and has no published outcome attached to it at all. The registrational program went 4, 9, 12.
• The 4mg dose is not a consolation prize. One escalation step, 19.0% average loss at 80 weeks, and a discontinuation rate for adverse events of 4.1% — lower than the 4.9% seen on placebo.
• Four weeks per step is faster than most people titrate. Holding a step longer is a tolerability trade, not a lost cause: the phase 2 arm that reached 8mg slowly still averaged 21.7% at 48 weeks, within 2.5 points of the 12mg group.

Twelve milligrams weekly is the highest dose tested in either obesity trial. Retatrutide has no FDA-approved label and is legally available only to participants in Lilly's clinical trials, so there is no official dose — the trial schedule is simply the only titration with published outcomes attached to it. If you are working out what routes actually exist, see how to get retatrutide.

What Happens in the First Week on Retatrutide (Days 1–7)

Week one is the lowest drug exposure you will ever have at a given dose, and that is pharmacokinetics rather than opinion. Retatrutide's half-life is approximately 6 days, measured in a phase 1b multiple-ascending-dose trial in people with type 2 diabetes. Each weekly injection therefore stacks on top of what is left of the last one, and a 6-day half-life implies levels keep climbing for roughly three to four doses before they plateau at any given step. Your first 2mg shot puts a fraction of the concentration in your system that you will be carrying by week 4 on that same 2mg.

Both trials started people at 2mg for exactly this reason, and phase 2 ran the experiment that shows why it matters. Two arms were assigned the same 8mg target: one started at 2mg and stepped up, the other started straight at 4mg. Same destination, very different first month.

Doubling the starting dose more than tripled the nausea rate and more than quadrupled vomiting to buy about two extra percentage points of weight loss at 48 weeks. Those adverse-event rates cover the whole study rather than week one specifically — the registry does not break them out by week. That is still the entire argument for starting low, and it is why a brutal first week on reta usually traces back to the opening dose rather than to the compound.

What to expect across the first seven days when you start taking retatrutide:

• Days 1–2: Most people feel very little. Mild soreness or itching at the injection site is common. Nausea in this window, if it shows up at all, is usually mild.
• Days 3–5: The window where appetite change is most often reported. In an exit-interview study of phase 2 participants, 31 of 36 people on retatrutide described changed eating behaviour — smaller portions, hunger arriving less often, feeling full sooner, shifted food preferences — within the trial's first eight weeks. The trials did not timestamp when inside that window it began; the day 3–5 timing is a consistent community report, not a trial finding.
• Days 6–7: Concentrations are at their trough before the next injection. Some people notice appetite creeping back the day before the next dose. This evens out as levels accumulate over the first month.
• The scale: Expect noise. No published trial reports a week-1 weight for retatrutide. An early drop is mostly food volume, water and glycogen, not fat.

If week one feels underwhelming, that is the expected result, not a bad batch or a non-response.

Phase 1: Weeks 1–4 (2mg) — Titration Starts

What Happens Physically

Week one usually starts with one clear signal: you're just not as hungry. Not dramatically, but noticeably. Portions that felt normal suddenly feel like too much. The background craving chatter most people don't realize they have — gets quieter.

No trial measured how much less people ate, so the "30–50% less by week 3" figure that circulates has nothing behind it. What was measured is qualitative: in the phase 2 exit interviews, participants described smaller portions, being hungry less often and feeling full sooner, all inside the first eight weeks. Some skip meals entirely and barely notice. A few feel slightly lightheaded when they push too hard with activity.

Side effect profile at 2mg:

• Nausea (mild to moderate): the most common complaint, though less universal than forum threads suggest — across the phase 2 safety window of up to 52 weeks, nausea was reported by 18% of the arm that started at 2mg and titrated to 4mg, and 17% of the arm that started at 2mg and titrated to 8mg. The registry does not break those rates out by week, so the familiar claim that nausea peaks after each dose step is a user report rather than a published finding
• Fatigue: common in week 1; usually resolves as the body adjusts
• Constipation: frequent, often underestimated — start a fiber protocol early
• Headache: mild, transient — usually related to reduced food intake
• Injection site reactions: minimal redness or itching in some people

The nausea at 2mg is almost always manageable. Smaller meals, slower eating, and dosing at night help. It's not the kind of nausea that sends most people to bed.

What the scale should show:

There is no published week-4 weight for retatrutide, so nothing here is a trial result. Carrying the 12mg arm's early rate of 0.72% per week out to four weeks gives about 3% — roughly 6 lbs for someone starting at 220 lbs — and the true figure is probably lower, because these are the 2mg weeks and levels have not plateaued yet. Some of the early drop is water and gut contents rather than fat. Don't expect dramatic changes here — this is the warm-up lap.

If you're stalling at 2mg:

If the scale hasn't moved by week 4, consider total caloric intake. Appetite suppression doesn't automatically mean you're in a deficit — some people unconsciously compensate with calorie-dense foods. Log what you eat for 3–5 days and see if the math adds up.

What to track:

• Weekly weight (same day, same time, after waking)
• Weekly waist circumference
• Daily water intake and bowel regularity
• Energy levels (1–10 scale)

Red flags at this phase:

• Vomiting more than 2–3 times per week — pause the dose and consult a provider
• Heart rate consistently above 90–100 bpm at rest
• Severe abdominal pain (not just bloating) — rule out pancreatitis

Phase 2: Weeks 5–8 (4mg) — First Real Momentum

What Happens Physically

The bump to 4mg is when retatrutide starts feeling like something. Appetite suppression becomes less predictable — some days it's dramatic, some days the hunger comes back briefly. This is normal. Your system is recalibrating.

The glucagon arm of the molecule is the one meant to raise energy expenditure, but that has only been shown in mice — no human energy-expenditure measurement has been published for retatrutide at any dose, and nothing ties an increase to week 5. Feeling warmer, better workouts and improved sleep around week 6–7 are user reports, not trial endpoints.

By retatrutide week 5, most people notice the shift from initial adaptation to something that feels more sustainable. The worst nausea from week 1 has passed. The appetite suppression at 4mg is more reliable than it was at 2mg, though it can still vary day to day. This is when the retatrutide week-by-week progression starts to feel like a genuine protocol rather than just managing side effects.

Side effect profile at 4mg:

• Nausea recurrence is common when the dose increases — usually milder than at 2mg because your gut has adapted somewhat
• Constipation often intensifies; this is the most underreported complaint
• Some people report reduced alcohol tolerance — widely described across GLP-1 drugs, though neither retatrutide obesity trial measured alcohol intake
• Reflux can emerge at this dose, especially if eating too close to bedtime
• Fatigue typically improves — unless you're chronically under-eating

The 4mg bump catches some people off guard because they feel great at 2mg, then feel temporarily worse again. This is temporary. Give it 10–14 days before deciding the side effects are unmanageable.

What the scale should show:

Again, no trial published a week-8 weight. The 12mg arm's early rate projects to roughly 4–6% cumulative by the end of week 8. You're in the most straightforward part of the protocol — appetite is controlled and the dose is still manageable.

If you're stalling at 4mg:

Protein intake is often the culprit. When appetite is suppressed, many people under-eat protein without realizing it. Aim for 0.7–1g per pound of body weight. This supports muscle retention and keeps metabolic rate from dropping too aggressively.

What to track:

• Continue weekly weight and waist
• Add: weekly photo (front, side) — this often shows changes the scale misses
• Note sleep quality — should be improving
• Track protein intake for at least one week

Red flags:

• Persistent daily vomiting — dose may need to stay at 2mg longer
• Severe reflux/GERD symptoms — adjust meal timing; consider antacid short-term
• Significant muscle weakness — under-eating is the likely cause; increase protein and calories slightly

Phase 3: Weeks 9–12 (6mg) — The Shift Becomes Visible

What Happens Physically

By week 9, people around you start noticing. Your face slims first. Then the waist. Clothes that fit tight in month 1 are loose now. Neither trial tracked visceral fat over time, so the idea that it starts mobilising specifically around week 9 is not something the data can support. What phase 2 did measure is waist circumference, down 14.3cm (5.6 in) at 12mg by week 24, and liver fat, down 82% at 12mg by week 24 in a substudy of 98 participants who had fatty liver disease at baseline.

The 6mg dose is when many people feel like retatrutide is doing exactly what they hoped. Appetite feels controlled without being oppressive. Energy is more stable. The worst GI symptoms are usually in the past.

Side effect profile at 6mg:

• GI side effects often stabilize at this dose — the worst is usually behind you
• Hair shedding: worth knowing that hair loss does not appear in the phase 2 registry adverse-event table or among TRIUMPH-1's most common adverse events, so there is no retatrutide figure for it. It is a labelled common side effect of tirzepatide, and shedding after fast weight loss is generally attributed to telogen effluvium rather than a direct drug effect. The week 10–12 timing is a community report
• Some report reduced libido temporarily — often related to caloric restriction rather than the drug itself
• Blood sugar drops can occur, especially if you're exercising more — keep a snack nearby

What the scale should show:

Phase 2 never published a week-12 average. Projecting the 12mg arm's early rate forward gives roughly 8–9% by week 12, not the 10–15% that gets quoted. Be careful with the trial numbers you'll see attached to week 12: the 17–18% figure that circulates is the week 24 result at 8–12mg, a full three months later. At week 12 a phase 3 participant had only just stepped onto 6mg.

If you're stalling at 6mg:

Metabolic adaptation starts to show up here. Your resting metabolic rate may have dropped as your body weight decreased. Adding 2–3 resistance training sessions per week (if you're not already) is the single most effective counter. It protects muscle and keeps total daily energy expenditure from sliding too much.

What to track:

• Progress photos monthly now
• If possible: DEXA scan or body fat measurement — the scale number matters less than body composition
• Continue weekly weight and waist
• Bloodwork: fasting glucose, lipid panel — likely showing real improvement now

Red flags:

• Unexplained rapid heart rate — phase 2 recorded a mean heart-rate rise at every dose, so a modest increase is expected; a resting pulse well outside your normal range is not, and warrants a provider conversation
• Signs of gallbladder issues (right-side abdominal pain after eating fatty foods) — one acute cholecystitis case occurred in a phase 2 8mg arm, and fast weight loss raises gallstone risk generally
• On thyroid: neither retatrutide obesity trial reported a thyroid signal, and phase 2's single raised-calcitonin serious event was in the placebo arm. The thyroid C-cell warning you may have read about belongs to the approved GLP-1 and GIP/GLP-1 drugs and comes from rodent studies

Phase 4: Weeks 13–20 (8mg) — Escalation and Acceleration

What Happens Physically

The 8mg dose is the pivot point of the protocol. No trial compared adherent against non-adherent users, so the split below is practitioner and community experience rather than a published analysis: people who maintain protein intake, keep lifting and don't try to under-eat their way to faster results tend to do well at 8mg, while people who crash calories down to 800 a day and skip everything else tend to feel exhausted.

On the waist, the published anchor is week 24 rather than week 20: the phase 2 8mg arms were down 13.7–15.0cm (5.4–5.9 in) by then, so a few inches at this point is consistent with the trial. Systolic blood pressure fell 8.8–11.8 mmHg at 48 weeks across those arms.

Side effect profile at 8mg:

• A subset of users experience a second wave of nausea — this is dose-dependent and should resolve within 2 weeks
• Heart rate runs higher. At 48 weeks the phase 2 8mg arms averaged +3.9 and +5.6 bpm against +0.9 on placebo — a group average, not a guarantee, and well short of a resting pulse in the 100s
• Injection site bruising or hardening can develop from consistent rotation — rotate your sites more frequently
• Appetite suppression can become almost too strong — some users need reminders to eat enough protein

What the scale should show:

The nearest published anchor is week 24, where the phase 2 8mg arms averaged 16.6% (slow titration) and 18.3% (fast titration) body weight loss. That's substantial. If you're tracking from 220 lbs, that puts you around 180–184 lbs at week 24. Note that the trial's first half was its fastest stretch, not its slowest: the 8mg slow-titration arm averaged 0.69% of body weight per week through week 24, closer to 1.3 lbs a week at that body size than to the half-pound weeks people brace for here. The slowdown comes later.

If you're stalling at 8mg:

A true plateau at 8mg that's lasted more than 3–4 weeks usually means one of three things: (1) your calorie deficit has closed as your metabolism adapted, (2) your body composition has shifted enough that your needs dropped, or (3) you've been gradually eating more without realizing it. For a detailed breakdown of plateau strategies, see Retatrutide Plateau: Why It Happens and How to Break It.

What to track:

• Monthly progress photos and measurements
• Track resting heart rate — should not consistently exceed 100 bpm
• Consider re-running bloodwork: metabolic panel, CBC, thyroid

Red flags:

• Resting heart rate consistently above 100 bpm — discuss with provider
• Severe fatigue that doesn't improve with adequate nutrition — check ferritin, B12, thyroid
• Gallbladder pain — rule out gallstones (gallstone risk increases with rapid weight loss)
• Any concerning changes in urination or vision — rule out undiagnosed diabetes-related complications

Phase 5: Weeks 21–32 (10–12mg) — High Dose Phase

What Happens Physically

This is peak retatrutide. The Phase 2 trial data showing 24.2% weight loss came from the 12mg cohort over 48 weeks. By this point in your protocol, the pharmacological effects are fully established, metabolic rate has been upregulated by the glucagon receptor pathway, and — if you've done the lifestyle work — your body composition is substantially different from where you started.

Not everyone needs to go to 12mg. Some people hold at 10mg — worth saying plainly that 10mg was a step in neither trial, so it has no published outcome data of its own and simply sits between the 9mg and 12mg phase 3 results. The decision to push to the maximum dose should be based on progress and tolerance, not just chasing a number.

At this dose, some users report a reduction in the "euphoric" effect that high-dose GLP-1 can produce. The appetite suppression is still there, but it feels more like a new baseline than a dramatic suppression.

Side effect profile at 10–12mg:

• GI symptoms generally stabilize for most people who tolerate this far
• Heart rate elevation is most notable — some users maintain a 5–15 bpm elevation
• Muscle loss risk increases if protein and training aren't prioritized
• Fatigue can re-emerge — distinguish between under-eating and genuine drug-related fatigue
• Some users report mood changes, including reduced motivation. Neither obesity trial reported a psychiatric adverse-event signal, and the dopamine and food-reward explanations offered for this have not been tested in retatrutide trials

For the heart rate question specifically, the phase 2 trial put numbers on it: at 48 weeks, mean heart rate was up 6.7 bpm on 12mg, 3.9–5.6 bpm on the 8mg arms, 2.6–3.6 bpm on the 4mg arms and 0.9 bpm on placebo. A 5–7 bpm group average is not the same as a resting pulse in the 100s, which is why the red flag below is set where it is.

What the scale should show:

Phase 2 week 24 data: −16.6% to −18.3% in the 8mg arms and −17.4% at 12mg, rising to −24.2% at 12mg by week 48. Week 32 sits between those two anchors and was never published. Interpolating at the trial's own post-week-24 rate of 0.28% per week puts it near 19–20% at 12mg — about 43 lbs from a 220 lb start, not the 44–53 lbs that a straight-line guess toward the week 48 figure would suggest. That late rate works out to roughly half a pound a week at this body size.

If you're stalling at 10–12mg:

Stalling at max dose is usually a metabolic adaptation issue. Options:

1. Diet break: 2 weeks at maintenance calories — this can reset leptin and reverse some adaptation
2. Training shift: Adding cardio or changing your resistance program to increase total energy expenditure
3. Dose cycle: Some practitioners use brief dose reductions followed by re-escalation
4. Accept the new normal: At high doses, "stalling" at a lower weight is often just the new set point — and may represent maximum drug effect

For dose-specific optimization, see the full Retatrutide Dosage Chart.

What to track:

• Lean mass preservation is now critical — consider DEXA scan
• Bloodwork every 8–12 weeks: full metabolic panel, lipid panel, thyroid
• Sleep quality — should be significantly improved if sleep apnea was a factor

Red flags:

• Rapid muscle mass loss — DEXA showing lean mass decline; increase protein and resistance training immediately
• Severe mood symptoms — this warrants a provider conversation
• Cardiac symptoms — palpitations, chest discomfort, significant tachycardia

Phase 6: Months 9–12 (Maintenance and Plateau Management)

What Happens Physically

The final phase of a 12-month protocol looks completely different from the first. You're no longer chasing rapid weight loss. You're building habits that will outlast the compound.

Month 9 is roughly week 39, another timepoint no trial published. Interpolating between the phase 2 week 24 and week 48 anchors puts the 12mg arm near 22% below baseline and the 4mg arm nearer 15%, so the honest range across doses is wide. The rate of loss has slowed — the trial's own second half ran at 0.28% per week against 0.72% in the first half. Some people mistake that for the drug "stopping working." It hasn't. The deficit required to keep losing has shrunk along with the body carrying it.

This phase is also when the psychological work of the protocol becomes most apparent. The appetite suppression that made everything feel easy in months 1–3 is now more like a background effect. The discipline required to stay consistent is genuinely yours now, not just the drug's.

Side effect profile at maintenance:

• Most GI side effects have long resolved
• Ongoing hair thinning may still be present. No retatrutide trial reported hair loss at all, so any month-by-month resolution timeline for it comes from user reports and the general telogen effluvium literature, not from this drug's data
• Some users report improved relationship with food — lower obsessive thinking, better hunger signals
• A subset experience fatigue from long-term caloric restriction — periodically reassess your intake

What the scale should show:

Phase 2 stopped at week 48, which is month 11, not month 12 — there is no month-12 figure from that trial. What it published at week 48 is −21.7% and −23.9% in the two 8mg arms and −24.2% at 12mg. Its late-phase rate of 0.28% per week works out to roughly half a pound a week at the body weights people are carrying by then. The question isn't whether you're losing fast — it's whether you're consolidating a new weight identity that will hold.

Handling plateau in months 9–12:

Plateaus here are common and expected. Standard approaches:

1. Reassess baseline caloric needs — they've changed significantly since month 1
2. Prioritize muscle-building to raise resting metabolic rate
3. Consider strategic maintenance phases to allow hormonal recovery
4. Some users cycle down from 12mg to 8mg during this phase. No trial tested dose reduction and re-escalation, so treat the claim that it "refreshes" the response as untested

What to track:

• Body composition over scale weight — this is the most meaningful metric now
• Non-scale victories: energy, sleep quality, lab values, fitness performance
• Psychological relationship with food — improved hunger signaling is a key outcome

Red flags:

• Re-emergence of binge eating or disordered patterns — warrants behavioral health support
• Significant weight regain between doses — may signal underdosing or poor timing
• Persistent labs outside normal range — ongoing provider monitoring essential

Beyond Month 12: What the Phase 3 Data Adds

The 12-month frame in this guide comes from the phase 2 trial, which ran 48 weeks and stopped. Phase 3 ran longer, and the extra time changed the shape of the curve.

TRIUMPH-1 randomised 2,339 adults with obesity, or overweight plus a weight-related condition and without diabetes, to retatrutide 4mg, 9mg, 12mg or placebo for 80 weeks. Average baseline: 112.7kg (248.5 lbs), BMI 40.0. Lilly reported topline results on 21 May 2026, with further detail presented at the ADA Scientific Sessions in June.

Those are efficacy-estimand numbers — what happened in people who stayed on the drug. The treatment-regimen estimand, which counts everyone regardless of whether they kept taking it, was −17.6%, −23.7% and −25.0% for 4mg, 9mg and 12mg. Real-world results tend to sit closer to the second set.

A pre-specified extension took 532 participants with a baseline BMI of 35 or higher out to 104 weeks, blind-escalating everyone to a maximum tolerated dose of 9mg or 12mg. That subgroup started heavier than the main trial — 121.7kg (268.3 lbs), BMI 42.8 — and the arm originally randomised to 12mg finished at −30.3%, an average of 85.0 lbs. Read the placebo row before extrapolating: participants moved from placebo onto retatrutide at week 80 reached −19.2% by week 104, so much of the extension's second year reflects starting the drug, not staying on it. For those already on 12mg, though, the line was still heading down two years in.

The practical implication for anyone reading a week-by-week timeline: month 12 is not the finish line, and the slowdown in months 9–12 is not the ceiling. It is the stretch of the curve where the trials simply kept going. Retatrutide remained investigational at the time of this readout and is not FDA-approved.

What to Track at Every Phase (And What Not to Obsess Over)

The scale is one data point. It's not the most important one.

Track weekly:

• Body weight (morning, post-bathroom, same day of week)
• Waist circumference
• Energy level (1–10)
• Sleep quality
• Side effect severity

Track monthly:

• Progress photos (front, side, back)
• Measurements: chest, waist, hips, thighs
• Bloodwork every 2–3 months: fasting glucose, lipids, metabolic panel, thyroid, CBC

Don't obsess over:

• Daily weight fluctuations (can swing 2–5 lbs from water)
• Comparing your timeline to someone else's
• Reaching a specific dose by a specific date

The metric that matters most is the trend over 4-week periods, not any single week.

Retatrutide Side Effects: The Honest Timeline

Side effects follow what users describe as a predictable arc. One caveat before the timeline: neither trial published adverse events by week. The registry reports a single rate per arm across the whole study, so the week-by-week shape below is community experience plus the fact that dose steps land every four weeks. It is not a trial finding.

Weeks 1–4: GI symptoms are most intense — nausea, constipation, early satiety making it hard to eat enough. Most manageable with small, frequent meals and adequate hydration.

Weeks 5–12: Symptoms recur briefly with each dose increase, then settle. Constipation is the most persistent issue. A daily fiber supplement and adequate water intake are not optional.

Months 3–6: GI issues largely resolve. Hair shedding may peak. Energy is usually the best it's been. This is often described as "the sweet spot."

Months 6–12: Side effects are minimal for most users on a stable dose. The main watchpoints are cardiovascular (heart rate) and metabolic (muscle preservation).

For a full breakdown by dose with management strategies, see Retatrutide Side Effects: What to Expect and How to Manage Them.

When Retatrutide Stops Working (And What That Really Means)

The word "plateau" gets thrown around loosely. Here's the reality:

There are two types of plateaus on retatrutide:

Type 1 — Metabolic adaptation: Your resting metabolic rate has dropped proportionally to your weight loss. This is expected and physiologically normal. The fix is usually a combination of resistance training, periodic caloric resets, and patience.

Type 2 — Receptor desensitization: This one is speculative. No published retatrutide study shows receptor desensitization causing a weight plateau, and the trial curves were still falling at week 48, week 80 and week 104. The one documented instance of tachyphylaxis is narrower: the drug's slowing of gastric emptying wanes over time, which is a tolerability effect rather than a weight-loss one. A brief dose reduction followed by re-escalation is a common practitioner approach, but no trial has tested it.

Both types are manageable. Neither means the compound has "failed." See Understanding the Retatrutide Plateau for detailed strategies.

Ready to Source Quality Retatrutide?

If you're researching peptide sources, Synthro Lab offers third-party tested retatrutide with documented purity.

Browse Synthro Lab →

Frequently Asked Questions

How quickly does retatrutide start working?

The trials never timestamped this. What is published is that 31 of 36 retatrutide-treated participants in the phase 2 exit interviews described eating less or feeling full sooner within the trial's first eight weeks. The 24–72 hour figure is a community report, not a study result. For weight itself, no trial published anything before week 24, and a 6-day half-life means blood levels are still climbing through the first month.

What dose do most people end up at long-term?

In phase 2 the 8mg and 12mg arms produced the most loss. In phase 3 the target doses were 4mg, 9mg and 12mg, reading −19.0%, −25.9% and −28.3% at 80 weeks. Lower doses came with fewer discontinuations: 4.1% stopped for adverse events at 4mg against 11.3% at 12mg, with placebo at 4.9%. The goal is the lowest dose that produces consistent results, not the highest dose possible.

Why is my weight loss slower than what clinical trials show?

Trial participants are often in highly controlled settings with dietary guidance, regular monitoring, and strict adherence protocols. Real-world results vary. Also, trial data at 12mg represents the maximum dose studied — many people titrate more slowly and may not reach that dose level within the same timeframe.

Is the hair loss permanent?

Hair loss was not reported as an adverse event in either retatrutide obesity trial, so there is no retatrutide-specific answer. It is a labelled common side effect of tirzepatide, and shedding after fast weight loss is generally attributed to telogen effluvium — a temporary disruption to the hair growth cycle rather than a direct drug effect, which is why it is expected to resolve. The week-8-to-16 onset window and the 3–6 month recovery figure come from the general telogen effluvium literature and user reports, not from retatrutide data.

What happens when you stop retatrutide?

No retatrutide withdrawal or maintenance trial has been published, so everything on this question is extrapolated from the GLP-1 class, where regain after stopping is well documented. The degree of regain is generally reported to depend on whether lifestyle habits were established during treatment — that too is class-level evidence rather than a retatrutide finding.

Can you stay on retatrutide indefinitely?

Safety and efficacy data now run to 80 weeks from the phase 3 TRIUMPH-1 trial, plus 104 weeks in a 532-participant BMI ≥35 extension subgroup. Discontinuation for adverse events in that trial was 4.1% at 4mg, 6.9% at 9mg and 11.3% at 12mg, against 4.9% on placebo. Nothing longer than two years is published, and retatrutide is still investigational. From a practical standpoint, many users treat it as a 12-month intervention to achieve a new weight baseline, then work on maintenance. Consult a provider for guidance on duration specific to your situation.

What should I do if I'm not losing weight at 4mg?

First, rule out diet creep — log your calories for 5 days to verify you're actually in a deficit. Second, assess protein — aim for 0.7–1g per pound of body weight. Third, consider whether you need a dose increase if you've been at 4mg for 6+ weeks without response. Some people simply need a higher dose to achieve the appetite suppression that drives results.

How much reta do I take a week?

Retatrutide is a once-weekly subcutaneous injection, and both published obesity trials started every participant at 2mg per week. TRIUMPH-1 then stepped the dose every four weeks: 2mg to 4mg for the 4mg target; 2 to 4 to 6 to 9mg for the 9mg target; 2 to 4 to 6 to 9 to 12mg for the 12mg target. Twelve milligrams weekly is the highest dose studied. Because there is no FDA-approved label, that trial schedule is the only titration with published outcome data behind it, and it is not medical advice.

How long before I lose weight on reta?

Appetite changes before the scale does. In the phase 2 exit-interview study, 31 of 36 participants on retatrutide reported eating less or feeling full sooner within the trial's first eight weeks. For weight itself, the trial averages work out to roughly 0.5–0.7% of body weight per week over the first 24 weeks — about 1 to 2 lbs a week in the 200–290 lb range, and slower than that during the 2mg and 4mg starting weeks. Give any trend four weeks before you judge it; below that, daily fluctuation is larger than the signal.

What are realistic expectations at 6 weeks?

At week 6 on the trial schedule you are in your second week at 4mg, and levels have not yet plateaued at that dose. Applying the trial's early-phase rates to six weeks gives roughly 2–4% of starting weight — 5 to 10 lbs for someone starting at 250 lbs — plus a clearly smaller appetite. No trial published a week-6 weight, so a precise six-week number from anywhere is a forum figure, not a study result.

Does fat loss speed up between week 12 and week 24?

That stretch is when the dose finally arrives. On the phase 3 schedule, weeks 13–16 are the first weeks at 9mg and week 17 is the first at 12mg, so weeks 12–24 are the first period where anyone is at full dose with concentrations at steady state. The published data cannot resolve week-to-week rates inside that window — phase 2 reported body weight at week 24 and week 48 only — but the comparison between those two anchors is unambiguous: at 12mg, 17.4 of the eventual 24.2 percentage points were already gone by week 24. Roughly 72% of the first year's loss happened in its first half.

Is it normal to start gaining weight after meeting your goal?

While you are still on the compound, a few pounds back after a low is usually not fat. Body weight swings 2–5 lbs on food volume, sodium, hydration and glycogen alone, and the trial curves kept trending down through week 80 and, in the BMI ≥35 extension, through week 104 — so a stall at month 9 or 12 is not a ceiling the data supports. A real regain is a four-week trend, not a bad morning. What no one can tell you from trial data yet is what happens after you stop: there is no published retatrutide withdrawal or maintenance trial. See stopping retatrutide for what is currently known.

Medical disclaimer: This content is for informational purposes only and is based on published clinical research. It does not constitute medical advice. Retatrutide is not FDA-approved for weight loss as of this writing. Always consult a qualified healthcare provider before starting, adjusting, or stopping any peptide protocol. Individual results vary. The information presented here reflects clinical trial data and should not be interpreted as guaranteed outcomes.

References

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (48-week dose-response, NEJM 2023) — PubMed
• Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 TRIUMPH-1 obesity trial — Eli Lilly
• Study Results: Once-Weekly LY3437943 (retatrutide) in Obesity, NCT04881760 — ClinicalTrials.gov
• LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: phase 1b multiple-ascending dose trial (half-life ~6 days, Lancet 2022) — PubMed
• Triple Agonism Based Therapies for Obesity (phase 2 heart rate, waist and responder data, Curr Cardiovasc Risk Rep 2025) — PMC
• Perceived benefits of treatment for obesity with retatrutide: qualitative exit-interview study of phase 2 participants (Obesity Pillars 2025) — PMC
• TRIUMPH-1 master protocol record, NCT05929066 (dose escalation schedule and trial design) — ClinicalTrials.gov
• Lilly's triple agonist retatrutide drove substantial improvements in weight, A1C, knee osteoarthritis pain and obstructive sleep apnea (TRIUMPH-1 detailed results, ADA 2026, 6 June 2026) — Eli Lilly
• Zepbound (tirzepatide) prescribing information (hair loss listed among common side effects) — DailyMed